## **Core Concept**
Isoniazide is a first-line antitubercular medication primarily metabolized in the liver. The metabolism of isoniazide involves acetylation, a process that affects its plasma concentration and duration of action. This metabolic pathway is crucial for understanding the variability in drug response among individuals.

## **Why the Correct Answer is Right**
The correct answer, , indicates that isoniazide is metabolized by acetylation. This process is primarily facilitated by the enzyme **N-acetyltransferase 2 (NAT2)**, which is located in the liver. Acetylation converts isoniazide into its major metabolite, **acetylisoniazid**, which is less active than the parent compound. The rate of acetylation categorizes individuals as either "slow acetylators" or "fast acetylators," influencing the drug's plasma levels and potential side effects.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because it does not accurately represent the primary metabolic pathway for isoniazid.
- **Option B:** This option is incorrect as it does not specify the correct metabolic process for isoniazid.
- **Option D:** This option is incorrect because it does not accurately describe the primary enzyme or process responsible for isoniazid metabolism.

## **Clinical Pearl / High-Yield Fact**
A key clinical consideration is that the acetylation status of a patient can influence the dosing and monitoring of isoniazid. **Slow acetylators** are at a higher risk of developing **peripheral neuropathy** due to higher plasma concentrations of isoniazid, and they may require lower doses. Conversely, **fast acetylators** may require higher doses to achieve therapeutic effects.

## **Correct Answer:** . Acetylation.